Current situation of oncology biosimilars in Japan

Affiliations

Comment

Sumimasa Nagai. Lancet Oncol. 2021 Mar.

. 2021 Mar;22(3):e82.

doi: 10.1016/S1470-2045(21)00029-2.

¹ Translational Research Center, The University of Tokyo Hospital, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Electronic address: sunagai-tky@umin.ac.jp.

No abstract available

Comment on

Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL, Schoen MW, Hoque S, Witherspoon BJ, Aboulafia DM, Hwang CS, Ray P, Yarnold PR, Chen BK, Schooley B, Taylor MA, Wyatt MD, Hrushesky WJ, Yang YT. Bennett CL, et al. Lancet Oncol. 2020 Dec;21(12):e575-e588. doi: 10.1016/S1470-2045(20)30485-X. Lancet Oncol. 2020. PMID: 33271114 Free PMC article. Review.